Nathan Hager

Person

Nathan Hager is the host of Bloomberg Daybreak, Bloomberg Radio's flagship morning show, where he covers global headlines.

What Nathan Hager has said on podcasts

12 statements

on The Home Depot, Inc.PositiveAug 18, 2026· Stock Movers
Home Depot is performing despite weakness in the housing market.
“Home Depot still finding a way”
Listen at 1:06
Open the episode · Home Depot Gains on Earnings; Baidu Slips on Outflows; Alibaba Jumps
on AstraZeneca–Bristol Myers Squibb merger approvalNegativeAug 3, 2026· Stock Movers
Nathan Hager doubts regulators will approve the AstraZeneca–Bristol Myers Squibb deal.
“you can't imagine these, or at least I can't imagine these two companies getting regulatory approval.”
Listen at 3:17
Open the episode · Bristol-Myers Squibb Potential Merger; SpaceX to Report; Tyson Drops
on U.S. administration mega-deal policyPositiveAug 3, 2026· Stock Movers
The current administration is viewed as favorable to pursuing mega-deals now.
“if you want a mega deal, now is the time.”
Listen at 3:29
Open the episode · Bristol-Myers Squibb Potential Merger; SpaceX to Report; Tyson Drops
on SpaceXNegativeJun 23, 2026· Stock Movers
SpaceX has not yet become profitable.
“SpaceX has yet to turn a profit.”
Listen at 1:59
Open the episode · SpaceX Slides and AMC Tumbles
on SpaceXNegativeJun 23, 2026· Stock Movers
SpaceX will continue burning cash through 2029.
“it's going to keep burning cash through 2029, according to S and P Global.”
Listen at 2:03
Open the episode · SpaceX Slides and AMC Tumbles
on AMC Entertainment Holdings, Inc.NegativeJun 23, 2026· Stock Movers
AMC shares fell more than 24%.
“AMC shares are sinking by more than 24%.”
Listen at 3:45
Open the episode · SpaceX Slides and AMC Tumbles
on AMC Entertainment Holdings, Inc.NegativeJun 23, 2026· Stock Movers
AMC's share sale could cause nearly 15% dilution for common stockholders.
“Bloomberg Intelligence is suggesting close to 15% dilution for common stockholders in American Multi Cinema.”
Listen at 4:01
Open the episode · SpaceX Slides and AMC Tumbles
on AbbVie acquisition of Apogee TherapeuticsPositiveJun 22, 2026· Stock Movers
AbbVie is acquiring Apogee Therapeutics for $10.9 billion.
“Abbvie is buying apogee for $10.9 billion”
Listen at 0:53
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
on Apogee TherapeuticsPositiveJun 22, 2026· Stock Movers
Apogee has a promising experimental psoriasis compound.
“that company's got a promising experimental compound for psoriasis”
Listen at 1:18
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
on Apogee psoriasis compoundPositiveJun 22, 2026· Stock Movers
Apogee’s psoriasis compound could rival Sanofi’s Dupixent.
“it could be a rival to France's Sanofi and its blockbuster Dupixit”
Listen at 1:25
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
on Placebo-controlled trials for rare-disease treatmentsNegativeJun 22, 2026· Stock Movers
Placebo trials are impractical for rare-disease treatments with very few annual patients.
“that's not practical when you're talking about experimental treatments for patients that might only be a few dozen a year”
Listen at 2:37
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline
on SpaceX borrowing for AI ambitionsNegativeJun 22, 2026· Stock Movers
SpaceX’s bond sale will likely begin massive borrowing to finance its AI ambitions.
“this is likely to be the start of a massive borrowing spree to finance Elon Musk's AI ambitions for the Rocket company”
Listen at 3:59
Open the episode · Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Nathan Hager

What Nathan Hager has said on podcasts

7 episodes featuring Nathan Hager

Akamai lands Anthropic deal as market movers split

Quarterback chaos meets Buffalo’s championship curse

Meta device buzz meets MGM deal uncertainty

Alibaba slides as quantum and travel stocks rally

Alibaba, On Holdings rise as Quest faces Medicare pressure

Big tech earnings put AI spending and monetization under the microscope

Earnings previews for Carnival, FedEx, and Darden signal consumer shifts